Background Literature has suggested that major depressive disorder (MDD) is accompanied
by higher concentrations of inflammatory biomarkers, which could sabotage response to …

Objective: Altered levels of peripheral inflammatory and proinflammatory cytokine markers
affect the different clinical stages of major depressive disorder (MDD). A concrete …

Background Anti-inflammatory agents have emerged as a potential new therapy for major
depressive disorder (MDD). In this meta-analysis, our aim was to evaluate the …

Objectives To systematically review the efficacy and safety of anti-inflammatory agents for
patients with major depressive disorders. Methods We searched the literature to identify …

The depressive state has been characterised as one of elevated inflammation, which holds
promise for better understanding treatment-resistance in affective disorders as well as for …

Background: Abundant evidence suggests that inflammatory cytokines contribute to the
symptoms of major depressive disorder (MDD) by altering neurotransmission …

A mounting body of literature indicates a dysregulated immune system as the underlying
pathogenetic mechanism of major depression (MD), at least in a subgroup of patients …

Background: With the growing importance of research about the association between
neuroinflammation and major depressive disorder (MDD), anti-inflammatory agents have …

Background Determining etiological factors and reviewing advances in diagnostic
modalities sensitive and specific to Major Depressive Disorder (MDD) is of importance in its …

Background No study has gathered evidence from all randomized clinical trials (RCT s) with
anti‐inflammatory drugs measuring antidepressant effects including a detailed assessment …